6 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow Rescue medication: new trials by email Literature Review of Rescue medication trials Research Report on Rescue medication
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 35 | 2024-12-20 | 2026-11-05 |
| Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD) Danirixin, Danirixin matching placebo, Standard of care - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 614 | 2017-04-25 | 2020-10-28 |
| A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma 800 μg AZD7594 once daily, 250 µg AZD7594 once daily, 58 µg AZD7594 once daily - Asthma, Efficacy | Phase 2 | Completed | AstraZeneca | 54 | 2015-06-25 | 2018-02-15 |
| A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) MK-1602, Placebo, Rescue medication - Migraine | Phase 2 | Completed | Allergan | 195 | 2012-08-01 | 2016-12-09 |
| A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) MK-1602, Placebo-matching MK-1602, Rescue medication - Migraine | Phase 2 | Completed | Allergan | 834 | 2012-07-01 | 2019-01-08 |
| Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED) Navarixin, Placebo, Rescue medication - Neutrophilic Asthma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 37 | 2008-05-01 | 2019-01-02 |
Migraine Disorders (2) · Asthma (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Pulmonary Disease, Chronic Obstructive (1)
Allergan (2) · Merck Sharp & Dohme LLC (2) · AstraZeneca (1) · GlaxoSmithKline (1)
Canada (2) · Germany (2) · Netherlands (2) · Spain (2) · United States (2) · Australia (1) · Bulgaria (1) · France (1) · Poland (1) · Romania (1) · South Korea (1) · United Kingdom (1)
Andrea Ludwig-Sengpiel, Dr. (1) · Anne-Marie Kirsten, Dr. (1) · Anneliese Linnhoff, Dr. med. (1) · Christine Grigat, Dr. (1) · Dirk Skowasch, Prof. (1) · Jutta Beier, Dr. med. (1) · Margret Jandl, Dr. (1) · Oliver Kornmann, Dr. (1) · Rainard Fuhr, Dr. med. (1) · Tanya Kralimarkova, Dr. (1) · Ulrike Westerhausen, Dr. (1)
PMID 22702508, PMID 30777086, PMID 39982105
2014 (1), 2016 (1)